Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery

Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) David J. Whellan, MD,* Pierluigi Tricoci, MD, PHD,y Edmond Chen, MD,z Zhen Huang, MS,y David Leibowitz, MD,x Pascal Vranckx, MD,k Gregary D. Marhefka, MD,* Claes Held, MD, PHD,{ Jose C. Nicolau, MD, PHD,# Robert F. Storey, MD, DM,** Witold Ruzyllo, MD,yy Kurt Huber, MD,zz Peter Sinnaeve, MD, PHD,xx A. Teddy Weiss, MD,x Jean-Pierre Dery, MD,kk David J. Moliterno, MD,{{ Frans Van de Werf, MD,xx Philip E. Aylward, MD,## Harvey D. White, DSC,*** Paul W. Armstrong, MD,yyy Lars Wallentin, MD, PHD,{ John Strony, MD,z Robert A. Harrington, MD,zzz Kenneth W. Mahaffey, MDzzz Philadelphia, Pennsylvania; Durham, North Carolina; Whitehouse Station, New Jersey; Jerusalem, Israel; Rotterdam, the Netherlands; Uppsala, Sweden; São Paulo, Brazil; Sheffield, United Kingdom; Warsaw, Poland; Vienna, Austria; Leuven, Belgium; Québec City, Québec and Edmonton, Alberta, Canada; Lexington, Kentucky; Adelaide, Australia; Auckland, New Zealand; and Stanford, California